LPLisa M. Pastore

Lisa M. Pastore

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Lisa M. Pastore has a total of 150 co-authors. Here are the top co-authors by number of shared publications:

  • Christopher D. Williams

    Reproductive Medicine and Surgery Center of Virginia

    9 shared publications
  • Logan B. Karns

    Department of Obstetrics and Gynecology, School of Medicine, University of Virginia, Charlottesville, VA

    6 shared publications
  • JoAnn V. Pinkerton

    Univ Virginia, Ctr Hlth, Dept Obstet & Gynecol, Charlottesville, VA 22904 USA

    4 shared publications
  • Lisa R. Rubin

    Department of Psychology The New School for Social Research New York NY USA

    4 shared publications
  • Steven L. Young

    UNC Fertility, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina

    4 shared publications
  • Devereux N. Saller

    Department of Obstetrics and Gynecology, University of Virginia, Charlottesville, VA, USA

    3 shared publications

Latest Publications

  • Ethical and moral perspectives of individuals who considered/used preimplantation (embryo) genetic testing

    by Jiahui Zhang, Lisa M. Pastore, Miriam Sarwana, Samantha Klein, Marci Lobel, Lisa R. Rubin

    This study examined perspectives on the ethical implications of preimplantation genetic testing (PGT) among individuals who actually (not hypothetically) used or considered using PGT. Most of the prior patient‐centered research on PGT ethics used qualitative designs (9 out of the 11 articles) and focused only on single gene testing. This cross‐sectional study used an anonymous online questionnaire; 15 items assessed potential ethical concerns involved in PGT decision‐making, including clinical indications for PGT, the greater implications of PGT for society, and unused embryo disposition. N = 207 individuals (mean female/male age 35.7/38.9 years, 21% Hispanic or non‐White) who had recently used or considered using PGT for single gene (60%) or for chromosomal testing (40%) completed the questionnaire. Most respondents supported PGT screening for disease conditions with childhood or adult onset that are untreatable (64%–85% across items); most opposed PGT for trait selection (76%–81%). Most respondents agreed that PGT aids in parental decision‐making (66%–67%), although some expressed concern over potential unforeseen consequences (25%–30%). Regarding disposition of embryos without known genetic abnormalities, most respondents favored freezing indefinitely (86%) or donating to another family (69%), while for embryos with genetic abnormalities, most respondents favored donating to research (78%) or destroying them (62%). Stratification by religious affiliation revealed several differences, such as less acceptance of PGT for diseases that occur in adulthood and have no treatment options among Protestants (p = .015) and greater willingness to donate surplus embryos to research among participants without a religious affiliation (p < .001). These results are limited by the relatively homogeneous sample of participants (mostly White, married, and predominantly college‐educated). In summary, participants who considered/used PGT found PGT acceptable overall for screening for disease conditions; most opposed using PGT for trait selection. Our novel questionnaire provides a structured tool for assessing the ethical perspectives surrounding the use of PGT.


  • Comparison of Patients’ Ethical Perspectives of Preimplantation Embryo Genetic Testing for Aneuploidy (PGT-A) vs. Monogenic Disorders (PGT-M)

    by J. Zhang, L. R. Rubin, H. Zierhut, L. M. Pastore

    What are the ethical perspectives of preimplantation genetic testing in patients using/considering PGT-A compared to those using/considering PGT-M? A 17-item questionnaire administered online was used to assess ethical perspectives in US patients who recently used/considered PGT-A (n=80) vs. those who used/considered PGT-M (n=72). Kruskal-Wallis, Chi-square, and Fisher exact tests were conducted with STATA. Most PGT-A and PGT-M users/considerers supported using PGT to screen for diseases fatal in childhood (86–89%) and those causing lifelong disabilities (76–79%) and opposed using PGT to screen for non-medical physical (80–87%) or intellectual traits (74–86%). Both groups agreed that PGT aids in parental decision-making, although some expressed concern over its potential to lead to unforeseen consequences for society and the PGT offspring. More PGT-M than PGT-A users/considerers opposed implanting genetically abnormal embryos when requested by parents (29% PGT-A vs. 56% PGT-M, p = 0.007). For embryo disposition, more PGT-A users/considerers favored freezing (95% PGTA vs. 82% PGT-M, p = 0.018) or donating genetically normal embryos to research (73% PGT-A vs. 57% PGT-M, p = 0.044), while more PGT-M users/considerers supported donating embryos with known genetic abnormalities to research (56% PGT-A vs. 81% PGT-M, p = 0.001). Regardless of the reason for using PGT, users generally agreed on the acceptable and unacceptable uses for it, as well as the potential societal impact. PGT-M users/considerers expressed more opposition than PGT-A users/considerers to implanting embryos with a genetic alteration when requested by the parents.


  • Initial psychometric analysis of novel instruments to assess decisional distress and decisional uncertainty in women who have considered using preimplantation genetic testing

    by Lisa M. Pastore, Lisa R. Rubin, Jennifer Nicoloro SantaBarbara, James Stelling, Marci Lobel

    OBJECTIVE To analyze psychometric properties of two novel instruments assessing decisional distress and uncertainty experienced by individuals considering preimplantation genetic testing (PGT). METHODS The new PGT Decisional Distress instrument (22 items) assesses negative/positive emotions. The new PGT Decisional Uncertainty instrument assesses Clarity about test benefits/disadvantages (5 items) and Certainty of having adequate information/support to make a good decision (7 items). Scales ranged from 0‐4. Psychometrics (central tendencies, internal consistency reliability, discriminant validity) were evaluated. Stratified analysis by decision stage was conducted. All participants had considered or used PGT in the previous 6 months. RESULTS N = 106 females (mean age 36.5 ± 4.8 years; 16% non‐Caucasian; 9% Hispanic) across 16 US states completed an online anonymous questionnaire. On average, respondents reported minimal distress (mean 0.96), high clarity (mean 3.26), and high certainty (mean 3.06), particularly those who had already decided compared to undecided women (P ≤ 0.02). Instruments had excellent internal consistency (Cronbach’s α’s 0.92‐0.94) and displayed sufficient inter‐individual variability (SD’s 0.75‐0.89). Correlations confirmed expected patterns of association between instruments (p’s < 0.01), indicating discriminant validity. CONCLUSION We document initial reliability and validity of new instruments to measure emotional distress and uncertainty in female patients who have recently considered PGT for single‐gene or chromosomal disorders.


  • Does theFMR1 gene affect IVF success?

    by Lisa M Pastore, Mindy S Christianson, Bailey McGuinness, Kamaria Cayton Vaught, Jacqueline Y Maher, William G Kearns


  • Open Access

    Patients’ preimplantation genetic testing decision-making experience: an opinion on related psychological frameworks

    by L M Pastore, C N Cordeiro Mitchell, L R Rubin, J Nicoloro-SantaBarbara, M C Genoff Garzon, M Lobel

    The process of deciding whether to pursue preimplantation genetic testing (PGT) of an embryo is highly stressful for individuals and couples and has adverse emotional consequences (e.g. distress and uncertainty). PGT influences patients’ lives in both positive and negative ways and is experienced at an individual level, as a dyadic unit, as a family member and as part of the society. Here, we argue that providing a conceptual framework with which to understand the `experience of decision making’ about PGT for monogenic disease (PGT-M) testing specifically, as well as the factors contributing to `decisional distress’ and `uncertainty’ that patients endure as a result—apart from what decision they make—is crucial to optimizing patient counseling, satisfaction and outcomes in the field of ART. Derived from psychological theory, the framework proposed here identifies three categories of contributing factors to decisional distress and uncertainty in considering PGT-M; namely, ‘intraindividual’, ‘interpersonal’ and ‘situational’ factors. We reviewed evidence from the PGT literature to inform our framework. Well-accepted theories of stress and health decision making were also reviewed for their relevance to PGT-M decision making, focusing on potential distress and uncertainty. Our novel conceptual framework can be used to inform clinical practice, to advance research and to aid the development of interventions for individuals and couples who are deciding whether or not to use PGT-M. Alleviating emotional distress and uncertainty can improve patients’ well-being during their reproductive journey.


  • Review of patient decision‐making factors and attitudes regarding preimplantation genetic diagnosis

    by M C Genoff Garzon, L R Rubin, M Lobel, J Stelling, L M Pastore

    The increasing technical complexity and evolving options for repro‐genetic testing have direct implications for information processing and decision making, yet the research among patients considering preimplantation genetic diagnosis (PGD) is narrowly focused. This review synthesizes the literature regarding patient PGD decision‐making factors, and illuminates gaps for future research and clinical translation. Twenty‐five articles met the inclusion criteria for evaluating experiences and attitudes of patients directly involved in PGD as an intervention or considering using PGD. Thirteen reports were focused exclusively on a specific disease or condition. Five themes emerged: (1) patients motivated by prospects of a healthy, genetic‐variant‐free child, (2) PGD requires a commitment of time, money, energy and emotions, (3) patients concerned about logistics and ethics of discarding embryos, (4) some patients feel sense of responsibility to use available technologies, and (5) PGD decisions are complex for individuals and couples. Patient research on PGD decision‐making processes has very infrequently used validated instruments, and the data collected through both quantitative and qualitative designs have been inconsistent. Future research for improving clinical counseling is needed to fill many gaps remaining in the literature regarding this decision‐making process, and suggestions are offered.


  • Top Cited Papers

    Reproductive ovarian testing and the alphabet soup of diagnoses: DOR, POI, POF, POR, and FOR

    by Lisa M. Pastore, Mindy S. Christianson, James Stelling, William G. Kearns, James H. Segars

    There are large variations in the number of oocytes within each woman, and biologically, the total quantity is at its maximum before the woman is born. Scientific knowledge is limited about factors controlling the oocyte pool and how to measure it. Within fertility clinics, there is no uniform agreement on the diagnostic criteria for each common measure of ovarian reserve in women, and thus, studies often conflict. While declining oocyte quantity/quality is a normal physiologic occurrence as women age, some women experience diminished ovarian reserve (DOR) much earlier than usual and become prematurely infertile. Key clinical features of DOR are the presence of regular menstrual periods and abnormal-but-not-postmenopausal ovarian reserve test results. A common clinical challenge is counseling patients with conflicting ovarian reserve test results. The clinical diagnosis of DOR and the interpretation of ovarian reserve testing are complicated by changing lab testing options and processing for anti-mullerian hormone since 2010. Further, complicating the diagnostic and research scenario is the existence of other distinct yet related clinical terms, specifically premature ovarian failure, primary ovarian insufficiency, poor ovarian response, and functional ovarian reserve. The similarities and differences between the definitions of DOR with each of these four terms are reviewed. We recommend greater medical community involvement in terminology decisions, and the addition of DOR-specific medical subject-heading search terms.


  • Psychological and emotional concomitants of infertility diagnosis in women with diminished ovarian reserve or anatomical cause of infertility

    by Jennifer M. Nicoloro-SantaBarbara, Marci Lobel, Silvina Bocca, James R. Stelling, Lisa M. Pastore


  • Distribution of the FMR1 gene in females by race/ethnicity: women with diminished ovarian reserve versus women with normal fertility (SWAN study)

    by Lisa M. Pastore, Steven L. Young, Ani Manichaikul, Valerie L. Baker, Xin Q. Wang, Joel S. Finkelstein


  • FMRI CGG Repeats:Reference Levels and Race-Ethnic Variation in Women With Normal Fertility (Study of Women’s Health Across the Nation)

    by Lisa M. Pastore, Ani Manichaikul, Xin Q. Wang, Joel S. Finkelstein

    FMR1 premutation carriers (55-199 CGG repeats), and potentially women with high normal (35-44) or low normal (FMR1 CGG repeat lengths from 803 women (386 caucasians, 219 African Americans, 102 Japanese, and 96 Chinese) from the US-based Study of Women’s Health Across the Nation (SWAN). Participants had ≥1 menses in the 3 months before enrollment, ≥1 pregnancy, no history of infertility or hormonal therapy, and menopause ≥46 years. Statistical analyses used Fisher exact tests. Among these women with normal reproductive histories, significant FMR1 repeat length differences were found across race-ethnicity for both the longer (P = .0002) and the shorter (P < .0001) alleles. The trinucleotide length variance was greater for non-Asian than Asian women (P < .0001), despite identical median values. Our data indicate that short allele lengths FMR1 distributions do vary by race–ethnicity, even within the “normal” range. This study indicates the need to control for race–ethnicity in FMR1 ovarian aging research and provides race–ethnic population data for females separated by allele.